Sec Form 4 Filing - Regan Andrew @ CONDUIT PHARMACEUTICALS INC. - 2024-06-14

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Regan Andrew 2. Issuer Name and Ticker or Trading Symbol CONDUIT PHARMACEUTICALS INC. [ CDT] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 4995 MURPHY CANYON ROAD,SUITE 300 3. Date of Earliest Transaction (MM/DD/YY) 06/14/2024 (Street) SAN DIEGO, CA92123 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 06/14/2024 J 1,100,000 D 30,048,454 I See Footnote ( 1 ) ( 2 ) Common Stock 06/14/2024 J 1,100,000 A 15,478,695 I See Footnote ( 1 ) ( 2 ) Common Stock 07/03/2024 S 1,000 D $ 0.64 15,477,695 I See Footnote ( 2 ) ( 3 ) Common Stock 07/08/2024 S 35,923 D $ 0.51 15,441,772 I See Footnote ( 2 ) ( 3 ) Common Stock 07/09/2024 S 77,681 D $ 0.4358 ( 4 ) 15,364,091 I See Footnote ( 2 ) ( 3 ) Common Stock 07/10/2024 S 150,000 D $ 0.3338 ( 5 ) 15,214,091 I See Footnote ( 2 ) ( 3 ) Common Stock 07/11/2024 S 582,952 D $ 0.2972 ( 6 ) 14,631,139 I See Footnote ( 2 ) ( 3 ) Common Stock 07/11/2024 S 300,000 D $ 0.29 ( 7 ) 14,331,139 I See Footnote ( 2 ) ( 3 ) Common Stock 07/12/2024 S 1,389,820 D $ 0.2471 ( 8 ) 12,941,319 I See Footnote ( 2 ) ( 3 ) Common Stock 07/15/2024 S 1,005,200 D $ 0.2471 ( 9 ) 11,936,119 I See Footnote ( 2 ) ( 3 ) Common Stock 07/16/2024 S 10,244,392 D $ 0.3169 ( 10 ) 1,691,727 I See Footnote ( 2 ) ( 3 ) Common Stock 07/17/2024 S 1,514,100 D $ 0.2583 ( 11 ) 177,627 I See Footnote ( 2 ) ( 3 ) Common Stock 66,650 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Regan Andrew 4995 MURPHY CANYON ROAD,SUITE 300 SAN DIEGO, CA92123 X X Corvus Capital Ltd. 4995 MURPHY CANYON ROAD,SUITE 300 SAN DIEGO, CA92123 X Algo Holdings, Inc. 4995 MURPHY CANYON ROAD,SUITE 300 SAN DIEGO, CA92123 X Signatures /s/ Andrew Regan 09/19/2024 Signature of Reporting Person Date Corvus Capital Limited By: /s/ Andrew Regan, Chief Executive Officer 09/19/2024 Signature of Reporting Person Date Algo Holdings, Inc. By: /s/ Alexander Lambert, Director 09/19/2024 Signature of Reporting Person Date

Explanation of Responses:

( 1 )On June 14, 2024, Corvus Capital Limited ("Corvus") transferred 1,100,000 shares of the Issuer's common stock, par value $0.0001 ("Common Stock"), to Algo Holdings, Inc. ("Algo"), its wholly-owned subsidiary for no consideration, pursuant to that certain Securities Transfer Request dated June 13, 2024. After giving effect to the transfer, Algo directly held 15,478,695 shares of Common Stock as of June 14, 2024. Andrew Regan is the Chief Executive Officer and sole shareholder of Corvus. Algo is a wholly owned subsidiary of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by each of Corvus and Algo. Dr. Regan disclaims any such beneficial ownership except to the extent of his pecuniary interest therein. This transfer reflects a change in the form of beneficial ownership and did not result in any change in Dr. Regan's and Corvus's pecuniary interest in such shares. ( 2 )Dr. Regan is the Chief Executive Officer and sole shareholder of Corvus. Algo is a wholly owned subsidiary of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by each of Corvus and Algo. Dr. Regan disclaims any such beneficial ownership except to the extent of his pecuniary interest therein. ( 3 )The securities are owned solely by Algo. On March 26, 2024, Algo pledged certain shares of Common Stock to a financial institution as collateral for a loan, pursuant to that certain Control and Restricted Loan Agreement, dated March 26, 2024, by and between Algo and such financial institution (the "Loan Agreement"). The loan proceeds were used to pay a portion of certain amounts due to a third party investor in the Issuer as an inducement to such investment to the Issuer in September 2023, pursuant to an agreement entered into by and among Algo, Corvus and such third party. These shares of Common Stock were sold by such financial institution pursuant to the terms and conditions of the Loan Agreement. ( 4 )The price reported in Column 4 is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $0.426-0.452, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range. ( 5 )The price reported in Column 4 is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $0.307-0.371, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the SEC, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range. ( 6 )The price reported in Column 4 is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $0.290-0.307, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the SEC, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range. ( 7 )The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.279-0.307, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range. ( 8 )The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.266-0.303, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range. ( 9 )The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.223-0.276, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range. ( 10 )The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.247-0.405, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range. ( 11 )The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.255-0.265, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range. Following the sales of shares of Common Stock as reported in this Form 4, Algo no longer holds 10% of the outstanding shares of Common Stock of the Issuer.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.